Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds a...

Full description

Bibliographic Details
Main Authors: Elio Gregory Pizzutilo, MD, Alberto Giuseppe Agostara, MD, Laura Roazzi, MD, Rebecca Romanò, MD, Valentina Motta, PhD, Calogero Lauricella, PhD, Giovanna Marrapese, PhD, Giulio Cerea, MD, Diego Signorelli, MD, PhD, Silvio Marco Veronese, PhD, Laura Giuseppina Giannetta, MD, Andrea Sartore-Bianchi, MD, Salvatore Siena, MD
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:JTO Clinical and Research Reports
Subjects:
Case report
Entrectinib
Repotrectinib
Resistance
ROS1 F2004V
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432300098X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432300098X

Similar Items